Crizotinib: a novel and first-in-class multitargeted tyrosine kinase inhibitor for the treatment of anaplastic lymphoma kinase rearranged nonsmall cell lung cancer and beyond
Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center)
Cited by 182